Becton, Dickinson and Company (NYSE:BDX) Announces Quarterly Earnings Results

Becton, Dickinson and Company (NYSE:BDX) released its quarterly earnings results on Thursday. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04, RTT News reports. The firm had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The firm’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter last year, the company earned $3.42 EPS. Becton, Dickinson and Company updated its FY 2025 guidance to 14.250-14.600 EPS and its FY25 guidance to $14.25-14.60 EPS.

Becton, Dickinson and Company Price Performance

BDX stock opened at $226.97 on Friday. The business’s fifty day moving average price is $237.53 and its 200 day moving average price is $235.16. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $257.58. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $65.60 billion, a PE ratio of 46.70, a P/E/G ratio of 1.76 and a beta of 0.43.

Becton, Dickinson and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be paid a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 1.83%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date is Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio is 78.19%.

Analysts Set New Price Targets

Several analysts recently commented on BDX shares. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price target for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. Raymond James dropped their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Evercore ISI raised their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Finally, Stifel Nicolaus upped their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.